ArticleAesthetic surgery journal2024
The Use of Hyaluronidase in Aesthetic Practice: A Comparative Study of Practitioner Usage in Elective and Emergency Situations.
Article in Aesthetic surgery journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- From permeation enhancer to therapeutic enabler: Advances, applications, and translational perspectives in hyaluronidase-based drug delivery.Materials today. Bio · 2026Review
- Reframing Hyaluronidase in Aesthetic Medicine: From "Dissolving Filler" to "Modifying Filler".Aesthetic surgery journal · 2026Article
- Cosmetic Medicine and Aesthetic Surgery Journal: The Beautiful Bond Between Noninvasive Aesthetic Medicine and Plastic Surgery.Aesthetic surgery journal · 2026Article
- Hyaluronidase Use in Aesthetic Medicine: Formulations, Safety, and Clinical Practice.Journal of clinical medicine · 2025Review
- Comparison of the Degradability of Hyaluronic Acid by Ovine and Recombinant Human Hyaluronidase.Aesthetic surgery journal · 2025Article
- Nonsurgical Approach to Treat Post-Rhinoplasty Vascular Complication With Hyaluronic Acid Injection.Journal of cosmetic dermatology · 2025Article
- Hyaluronidase Availability Beyond the Aesthetic Office: A Shared Responsibility for Safety in Filler Complications.Aesthetic surgery journal · 2025Article
- Response to: Hyaluronidase Availability Beyond the Aesthetic Office: A Shared Responsibility for Safety in Filler Complications.Aesthetic surgery journal · 2025Article
- Risk Factor Analysis for Vascular Occlusions After Dermal Filler Injections: A Systematic Review and Meta-Analysis.Cureus · 2025Review
- Considerations for Proper Use of Hyaluronidase in the Management of Hyaluronic Acid Fillers.Plastic and reconstructive surgery. Global open · 2025Article
- Effectiveness of Hyaluronidase on Hyaluronic Acid Degradation: An Experimental Study.Aesthetic surgery journal. Open forum · 2025Article
- Modulating rheology and bioactivity in dermal fillers: the emerging role of platelet-rich plasma (PRP).Frontiers in medicine · 2025Review
- Decomposition and Changes in In Vivo Post-HA Filler Injection: A Review.Journal of cosmetic dermatology · 2025Review
- Adverse Effects Associated with Dermal Filler Treatments: Part II Vascular Complication.Diagnostics (Basel, Switzerland) · 2024Review
- Fundamental considerations for the use of hyaluronidase, an enzyme for degrading HA fillers.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyaluronic acids (HAs) continue to be the fillers of choice worldwide and their popularity is growing. Adverse events (AEs) are able to be resolved through the use of hyaluronidase (HYAL). However, routine HYAL use has been at issue due to perceived safety issues.
objectivesThere are currently no guidelines on the use of HYAL in aesthetic practice, leading to variability in storage, preparation, skin testing, and beliefs concerning AEs. This manuscript interrogated the use of this agent in daily practice.
methodsA 39-question survey concerning HYAL practice was completed by 264 healthcare practitioners: 244 from interrogated databases and 20 from the consensus panel. Answers from those in the database were compared to those of the consensus panel.
resultsCompared to the database group, the consensus group was more confident in the preparation of HYAL, kept reconstituted HYAL for longer, and was less likely to skin test for HYAL sensitivity and more likely to treat with HYAL in an emergency, even in those with a wasp or bee sting anaphylactic history. Ninety-two percent of all respondents had never observed an acute reaction to HYAL. Just over 1% of respondents had ever observed anaphylaxis. Five percent of practitioners reported longer-term adverse effects, including 3 respondents who reported loss of deep tissues. Consent before injecting HA for the possible requirement of HYAL was always obtained by 74% of practitioners.
conclusionsHyaluronidase would appear to be an essential agent for anyone injecting hyaluronic acid filler. However, there is an absence of evidence-based recommendations with respect to the concentration, dosing, and treatment intervals of HYAL, and these should ideally be available. LEVEL OF EVIDENCE: 5:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.